A Phase 1/2, Open-label, Single-arm, Window of opportunity Study of ASP-1929
Photoimmunotherapy with Fluorescence Imaging in Patients with Operable Primary or Recurrent
Head and Neck or Cutaneous Squamous Cell Carcinoma
All patients will receive a combination of ASP-1929 and Photoimmunotherapy (PIT). During
illumination procedure, fluorescence of the IR700 of ASP-1929 will be imaged at a wavelength
in the vicinity of 830 nm with a Shimadzu Fluorescence Imaging System camera. Patients will
undergo standard of care surgery approximately 15 days after ASP-1929 PIT treatment.
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.